A technique that transforms immune cells into cancer-seeking bloodhounds may overcome a roadblock that has hampered immunotherapy for solid tumors, according to a new study by Stanford Medicine ...

FDA fast track designation supports development of pelareorep plus bevacizumab/FOLFIRI in 2L KRAS-mutant MSS mCRC, enabling more frequent regulatory engagement and potential accelerated pathways.

AXL, a member of the TAM receptor family, has emerged as a potential target for advanced-stage human malignancies. It is frequently overexpressed in different cancers and plays a significant role in ...

Alnodesertib, combined with irinotecan, targets ATM-negative metastatic colorectal cancer, showing promise in the STELLA study with favorable safety and clinical activity. The FDA's fast track ...

In 2022, almost 20 million cancer diagnoses and 10 million related deaths were reported globally 1. Approximately one in five individuals develops cancer in a lifetime 1, making it the second leading ...